Proteus Digital Health, Inc

proteus.com

Welcome to Proteus Digital Health, a leading innovator spearheading the Digital Medicines revolution. Join our unique collection of innovative engineers, scientists, designers, developers, clinicians, and other digital health pioneers, and assist us with achieving our compelling vision, “Healthcare for Everyone, Everywhere.” Proteus is creating a new category of pharmaceuticals: Digital Medicines. Digital Medicine includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making, and data analytics to serve the needs of doctors and health systems. The goal of Digital Medicine is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

GENSCRIPT RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR WORLD'S FIRST SARS-COV-2 NEUTRALIZING ANTIBODY DETECTION KIT

GenScript | November 09, 2020

news image

GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus. Neutralizing antibodies, a subset of antibodies that are specifically able to block the ability of the virus to enter a cel...

Read More

PHARMACY MARKET

MEDIPHARM LABS ENTERS UNITED STATES PHARMACEUTICAL MARKET WITH SUBMISSION OF FDA DMF

MediPharm Labs Corp. | February 24, 2022

news image

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects wil...

Read More

BUSINESS INSIGHTS

AKORN ANNOUNCES FDA-APPROVED GENERIC CETRORELIX ACETATE FOR INJECTION 0.25 MG

Akorn Pharmaceuticals | August 17, 2022

news image

Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg. This is the first approved AP-Rated bioequivalent version of Merck Serono's Cetrotide®.1 "We are pleased to announce the first approved AP-rated generic option for women receiving fertility treatments. As an increasing number of infants are being conceived via the use of ART, ...

Read More

PHARMA TECH

PHANES THERAPEUTICS REVEALS SPECPAIR™ TECHNOLOGY PLATFORM THAT ENHANCES MANUFACTURABILITY OF BISPECIFIC ANTIBODIES

Phanes Therapeutics | September 13, 2021

news image

Phanes Therapeutics, Inc., an emerging leader in innovative drug discovery research and development in immuno-oncology announced today that it has developed a proprietary technology platform, SPECpair™, which enables the use of the conventional monoclonal antibody (mAb) manufacturing process in the production of native IgG-like bispecific antibodies. This is the third technology platform Phanes has developed since the launch of the PACbody™ and ATACCbody™ platforms, which are d...

Read More
news image

RESEARCH

GENSCRIPT RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR WORLD'S FIRST SARS-COV-2 NEUTRALIZING ANTIBODY DETECTION KIT

GenScript | November 09, 2020

GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus. Neutralizing antibodies, a subset of antibodies that are specifically able to block the ability of the virus to enter a cel...

Read More
news image

PHARMACY MARKET

MEDIPHARM LABS ENTERS UNITED STATES PHARMACEUTICAL MARKET WITH SUBMISSION OF FDA DMF

MediPharm Labs Corp. | February 24, 2022

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects wil...

Read More
news image

BUSINESS INSIGHTS

AKORN ANNOUNCES FDA-APPROVED GENERIC CETRORELIX ACETATE FOR INJECTION 0.25 MG

Akorn Pharmaceuticals | August 17, 2022

Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg. This is the first approved AP-Rated bioequivalent version of Merck Serono's Cetrotide®.1 "We are pleased to announce the first approved AP-rated generic option for women receiving fertility treatments. As an increasing number of infants are being conceived via the use of ART, ...

Read More
news image

PHARMA TECH

PHANES THERAPEUTICS REVEALS SPECPAIR™ TECHNOLOGY PLATFORM THAT ENHANCES MANUFACTURABILITY OF BISPECIFIC ANTIBODIES

Phanes Therapeutics | September 13, 2021

Phanes Therapeutics, Inc., an emerging leader in innovative drug discovery research and development in immuno-oncology announced today that it has developed a proprietary technology platform, SPECpair™, which enables the use of the conventional monoclonal antibody (mAb) manufacturing process in the production of native IgG-like bispecific antibodies. This is the third technology platform Phanes has developed since the launch of the PACbody™ and ATACCbody™ platforms, which are d...

Read More